Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

Jun 25, 2021, 01:26 PM

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.

Audioboom uses Javascript

Please enable it in your browser's preferences.

You can visit our support center if you're having problems.

Sorry, your browser isn't supported by Audioboom.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.

Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

Subscribe

Next

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Top episodes

Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD

Diabetes Technology Updates in January 2024

Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

Sorry, your browser isn't supported by Audioboom.

Page load failed